# Fasting-mimicking diet Rating: Promising — Some human trials, or consistent animal work with a clear mechanism Type: Diet Updated: 2026-10-14 Canonical: https://heretic.bio/articles/fasting-mimicking-diet.html > The fasting-mimicking diet is a 5-day, very-low-calorie, low-protein protocol designed to trigger fasting physiology while allowing some food, commercialized as ProLon. Randomized trials report reduced visceral and liver fat, lower IGF-1 and HOMA-IR, and a ~2.6-year median drop in measured biological age after three cycles, though 21–31% of participants moved the wrong way. Two oncology adjunct trials are running but report after 2029. > The Fasting-Mimicking Diet (FMD) — popularized as the ProLon® protocol — provides the biological benefits of prolonged water fasting (autophagy, stem cell activation, metabolic reset) while allowing limited caloric intake. Developed by Dr. Valter Longo at USC, it represents the most researched structured fasting protocol with human clinical trial data demonstrating effects on biomarkers of aging, metabolic health, and systemic inflammation. ## Background and Development ### Origin * Developed by **Dr. Valter Longo** , director of the USC Longevity Institute * First published research in 2015 (Brandhorst et al., _Cell Metabolism_) * Commercialized as **ProLon®** (L-Nutra); first FDA-approved "fasting-mimicking" food product ### Theoretical Foundation * FMD triggers fasting metabolic state while providing minimal calories * Fasting state activates: autophagy, AMPK, sirtuins, stem cell regeneration * Unlike water fasting: reduced risk, better compliance, gut-sparing ## Uses ### Daily Calorie Distribution Day | Calories | Carbohydrate | Protein | Fat ---|---|---|---|--- **Day 1** | ~1,100 kcal | 55% | 15% | 30% **Days 2-5** | ~800 kcal | 45% | 15% | 40% ### ProLon-Style Menu (Typical) * **Day 1:** Nut-based bar, olive oil, soup, supplement packets * **Days 2-5:** Reduced portions of nuts, soups, chips, supplement drinks * **Total caloric intake:** ~5,500-5,800 kcal over 5 days (~800-1,100 kcal/day) * **Key features:** Plant-based, low protein, moderate fat, specific micronutrient formulation ### What Makes It "Fasting-Mimicking" * Extremely low protein (9-10% of calories) — minimizes mTOR activation * Very low insulin response * Ketone production begins Day 2-3 * IGF-1 reduction of 30-50% * Autophagy markers increase ## Clinical Evidence ### Key Study Findings #### 1\. Brandhorst et al. 2015 (_Cell Metabolism_) * **Design:** Randomized crossover trial, 100 participants * **Findings:** * Reduced body weight (4.5%), waist circumference * Lowered blood pressure, IGF-1, C-reactive protein * Increased stem cell markers * No serious adverse events #### 2\. Wei et al. 2017 (_Science Translational Medicine_) * **Design:** Clinical trial, various markers * **Findings:** * Reduced metabolic disease risk markers * Improved insulin sensitivity * Decreased trunk fat #### 3\. Brandhorst et al. 2024 (_Nature Communications_) — Biological Age Reduction [PMID: 38378685](https://pubmed.ncbi.nlm.nih.gov/38378685/) * **Primary findings:** * **Median biological age decreased by 2.6 years** after 3 FMD cycles (pooled n=86; p<0.001); mean reduction ~1.5 years; modal reduction >3.5 years * Improvement was **independent of weight loss** (re-analysis adjusting for BMI change remained significant, p=0.029; second trial p<0.001) * **Hepatic fat fraction reduced ~50%** in NAFLD subgroup (14.32% → 7.94%, p=0.02; MRI-measured) * **Visceral adipose tissue (VAT)** reduced (p=0.002); subcutaneous adipose tissue (SAT) reduced (p=0.008) — supports FMD's selectivity for visceral fat * **Lymphoid-to-myeloid (L/M) ratio increased** (p=0.005) — a reversal of age-related immunosenescence previously shown in mice * **HOMA-IR reduced** in pre-diabetics (1.47 → 1.21, p=0.046); **HbA1c reduced** (5.8 → 5.43, p=0.032) * **Mortality-risk simulation (NHANES-derived):** * 20-year all-cause mortality risk reduced 10.5% * Heart-disease mortality risk reduced 17.4% * Cancer mortality risk reduced 6.4% * Cerebrovascular mortality risk reduced 22% * Diabetes mortality risk reduced 26% * **Responder caveat:** 21–31% of participants showed _increased_ biological age; non-responders had lower baseline CRP and systolic BP, suggesting regression-to-the-mean or acute biomarker fluctuations rather than true worsening. #### 4\. Clinical Nutrition 2025 — Protein Content Trial (randomised parallel-group, healthy adults, n=45) * **Design:** Randomised comparison of 7-day FMD with **low-protein (LP-FMD)** vs **high-protein-to-fat-ratio (HP-FMD)** vs non-intervention control; matched for carbohydrate content * **Primary outcome:** Fasting plasma glucose (reduced similarly in both arms: LP-FMD −10%, HP-FMD −10%, both p<0.05 vs control) * **Mechanistic findings (both FMD arms):** * **IGF-1 reduced** (−9.0 nmol/L LP-FMD, p<0.0001; −5.4 nmol/L HP-FMD, p=0.024); insulin unchanged * **β-hydroxybutyrate elevated** more in LP-FMD (+1.17 mmol/L) than HP-FMD (+0.53 mmol/L, p=0.015) * **Autophagy gene transcripts upregulated** — _ULK1, BECN1, MAP1LC3A, ATG2A, BNIP3, GABARAPL1, ZFPM1, ATG4B_ * **Plasma BCAAs increased** despite low protein intake — likely marker of tissue autophagy activation * **Differential effects (HP-FMD only):** * Selective **visceral fat reduction** (not seen with LP-FMD) * Improved **heart-rate variability** (RMSSD) * Improved **lipid profile** (LDL, HDL) * Increased **gut microbiome diversity** * **Interpretation:** Total caloric restriction — not protein restriction alone — is the dominant driver of glucose/IGF-1 reduction and autophagy induction. Protein-to-fat ratio modulates body-composition, cardiac-autonomic, lipid, and microbiome outcomes, suggesting FMD can be **tailored to individual goals**. ### Biomarker Changes Marker | Direction | Magnitude ---|---|--- **IGF-1** | ↓ | 30-50% reduction **C-reactive protein** | ↓ | 30-50% reduction **Blood glucose** | ↓ | 10-20% reduction **Triglycerides** | ↓ | 15-25% reduction **Blood pressure** | ↓ | 5-10 mmHg systolic **Stem cell markers** | ↑ | Variable **Ketones** | ↑ | Becomes elevated Day 2-3 ## Applications ### 1\. Longevity / Healthy Aging * **Rationale:** FMD cycles may "reset" aging biomarkers * **Protocol:** 3-5 day FMD once per quarter * **Evidence:** Animal data strong (lifespan extension in mice); human data on biomarkers promising ### 2\. Metabolic Health / Weight Management * **Rationale:** Improves insulin sensitivity, reduces visceral fat * **Evidence:** Strong clinical data ### 3\. Autoimmune / Inflammatory Conditions * **Rationale:** Reduces systemic inflammation; potential for immune reset * **Evidence:** Longo lab showed reduced CRP; IBD mouse model data strong * **Applications:** Rheumatoid arthritis, multiple sclerosis, IBD ### 4\. Cancer Adjunct Therapy * **Rationale:** Fasting sensitizes cancer cells to chemotherapy (differential stress resistance) * **Evidence:** Animal data strong; human trials ongoing * **Note:** Must be done under oncologist supervision ### 5\. Gut Health * **Rationale:** Promotes intestinal stem cell regeneration; reduces gut inflammation * **Evidence:** Mouse data shows protection against IBD; human data emerging * **Protocol:** 1-2 day FMD monthly for gut health maintenance ## Uses ### Commercial * **ProLon®:** Original, research-backed, complete meal kit * **Other:** Generic FMD recipes available online (less validated) ### DIY Approach * **Concept:** Replicate macro/calorie profile without commercial product * **Risks:** Less precise; less research validation * **If DIYing:** Focus on <800 kcal, <10% protein, plant-based ## Comparison: FMD vs Water Fasting Aspect | Fasting-Mimicking Diet | Water Fasting ---|---|--- **Calories** | 800-1,100/day | 0 **Safety** | Good | Moderate (electrolyte risk) **Compliance** | Higher | Lower **Gut protection** | Yes (food) | No **Autophagy** | Induces (slightly less) | Strong induction **Muscle preservation** | Better | Risk of muscle loss **Research** | Multiple RCTs | Limited modern RCTs **Accessibility** | Commercial kit needed | No special products ## Contraindications ### Do NOT Use FMD If * **Pregnant or breastfeeding** — caloric restriction inappropriate * **Underweight (BMI <18.5)** — not appropriate * **Type 1 diabetes** — risk of hypoglycemia * **Eating disorder history** — may trigger disordered eating * **Active infection** — need adequate nutrition * **Children/adolescents** — growing bodies need consistent nutrition * **Certain medications** — consult provider (especially diabetes medications) ### Use With Caution * **Type 2 diabetes** — requires medication adjustment * **High stress / HPA axis dysfunction** — fasting adds stress * **Athletes in competition** — may impair performance ## Side Effects Generally mild and transient: \- **Hunger** (Day 1-2 most pronounced) \- **Headache** (common; usually resolves) \- **Fatigue** (especially Days 2-3) \- **Constipation** (use caution) \- **Dizziness** (usually mild) \- **Mood changes** (irritability common early) **Note:** Most side effects diminish with repeated cycles as body adapts. ## 2026 Update — Active Trials and New Evidence ### Cancer Adjunct Trials (Active as of Sep 2026) Two phase-2 trials opened in 2026 explicitly test FMD as an adjunct to modern chemo-immunotherapy combinations: #### [NCT07378306](https://clinicaltrials.gov/study/NCT07378306) — FACT-TN (Triple-Negative Breast Cancer) * **Sponsor:** Sun Yat-sen University, Guangzhou. **Phase 2, single-arm, open-label, n=80.** Start: 2026-03-05; Primary completion: 2029-06. * **Population:** Operable early or locally advanced TNBC / near-TNBC. * **Rationale:** TNBC patients without pathologic complete response (pCR) after neoadjuvant chemo-immunotherapy recur at high rates; FMD's preclinical immunomodulation (anti-tumor immunity activation) provides a mechanistic lever. * **Endpoint:** pCR rate and safety. #### [NCT07500831](https://clinicaltrials.gov/study/NCT07500831) — FMD + Toripalimab + Axitinib (Metastatic Renal Cell Carcinoma) * **Sponsor:** Qilu Hospital of Shandong University. **Single-arm, open-label.** Last update posted 2026-03-30; not yet recruiting. * **Population:** Metastatic or unresectable clear-cell-predominant RCC, first-line. * **Rationale:** IO-TKI is the new first-line standard; preclinical FMD data show synergy with chemo, immunotherapy, and targeted therapy in mice. This is the first trial testing FMD with the modern IO-TKI backbone. **Together:** Two oncology indications + two distinct FMD schedules (per-chemo- vs per-IO-TKI-cycle). FACT-TN is the larger, earlier-stage trial; [NCT07500831](https://clinicaltrials.gov/study/NCT07500831) is the first-line metastatic one. Both will report after 2029. ### New Mechanistic / Metabolic Evidence (2025–2026) * **Abdominal adiposity RCT** — _Clinical Nutrition_ 2025 (S0939-4753(25)00265-0): A **fasting-mimicking diet programme reduces abdominal adiposity** in a randomized trial. Reinforces the visceral-fat selectivity noted in the 2025 protein-content study and in the 2024 Brandhorst _Nat Commun_ paper. * **Skeletal muscle preservation** — _European Journal of Applied Physiology_ (2022, PMID [35034194](https://pubmed.ncbi.nlm.nih.gov/35034194/)): single cycle of FMD does **not** reduce skeletal muscle function in healthy young adults — addresses the most common clinical objection to periodic fasting. * **Longo 2025 review** — _Nat Rev Endocrinol_ 21(2):73-74: positions FMD as a clinically actionable tool for obesity and T2DM, distinct from intermittent fasting protocols. * **DIRECT trial (re-citation)** — _Nat Commun_ 2020 (PMID [32576828](https://pubmed.ncbi.nlm.nih.gov/32576828/)): FMD + neoadjuvant chemotherapy in HER2-negative breast cancer (BOOG 2014-01, phase 2 RCT). Established feasibility/safety of FMD with chemo; the 2026 FACT-TN trial is its chemo-immunotherapy successor. ### Open Mechanistic Questions * Why **21–31% of participants in the 2024 Brandhorst pooled analysis show increased biological age** despite the population mean improvement? The responder-caveat hypothesis (regression-to-the-mean / acute biomarker fluctuations in low-CRP / low-BP non-responders) is plausible but unconfirmed. No 2026 paper has yet re-analyzed this subgroup. * Whether FMD's effects on lymphoid-to-myeloid ratio (immunosenescence reversal) translate into **clinically meaningful infection or vaccine-response outcomes** in older adults — the Brandhorst 2024 paper showed the biomarker shift but not its clinical correlate. * Optimal **frequency for chronic use** : the 2024 trial used 3–4 monthly ; whether quarterly or twice-yearly is sufficient for biological-age benefit is unknown. The [NCT07378306](https://clinicaltrials.gov/study/NCT07378306) schedule (every 3 weeks × 8) is for active cancer therapy, not maintenance. **Related:** [Fasting Protocols](fasting-approaches.html) | [Autophagy](autophagy.html) | [mTOR and AMPK Pathways](mtor-and-ampk-pathways.html) | [Overview - Longevity Science](longevity-science-overview.html) | [Metabolic Health and Insulin](metabolic-health-and-insulin.html) | NAFLD and Liver Health | Biological Age and Epigenetic Clocks | [Senolytics](senolytics.html) | [Rapamycin Dosing Protocols](rapamycin-mtor-inhibition-pearl-trial-evidence-and-clinical-translation.html) ## Sources 1. Brandhorst S et al. (2024). "Fasting-mimicking diet causes hepatic and blood markers changes indicating reduced biological age and disease risk." Nature Communications . PMID 38378685 -- pooled n=86; median biological age -2.6 yr; weight-loss-independent. (PubMed 38378685) 2. Brandhorst S et al. (2015). "A Periodic Diet that Mimics Fasting Promotes Multi-System Regeneration." Cell Metabolism . PMID 25940989 (PubMed 25940989) 3. Longo VD & Mattson MP. (2014). "Fasting: Molecular Mechanisms and Clinical Applications." Cell Metabolism . PMID 24440038 (PubMed 24440038) 4. NCT07378306 (NCT07378306) 5. NCT07500831 (NCT07500831) 6. PubMed 35034194 (PubMed 35034194) 7. PubMed 32576828 (PubMed 32576828)